Pemetrexed Market, By Strength (100 mg ,500 mg), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

PUBLISHED: February 13, 2026

PAGES: 152 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Pemetrexed Market is estimated to be valued at USD 2,494.2 Mn in 2026 and is expected to reach USD 2,907.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,494.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	2.20%	2033 Value Projection:	USD 2,907.6 Mn

Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by US FDA (Food and Drug Administration) in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. As a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous (non-small cell lung cancer) NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is a single agent for the treatment of patients with recurrent, metastatic non-squamous (non-small cell lung cancer) NSCLC after prior chemotherapy.

Market Dynamics

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to drive global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, an international pharmaceutical company the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly. The launch helped the company in further expansion in pharmaceutical sector.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for pemetrexed drive global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, an oncology organization, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Furthermore, key players in the market are dedicated to expand the indication of its pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

Key features of the study

This report provides an in-depth analysis of the global pemetrexed market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global pemetrexed market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy's Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc..
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global pemetrexed market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pemetrexed market.

Market Segmentation

Strength Insights (Revenue, USD Mn, 2026 - 2033)
- 100mg
- 500mg
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Eli Lilly and Company
- Stada Arzneimittel AG
- Eagle Pharmaceuticals, Inc
- Fresenius Kabi USA
- Teva Pharmaceuticals USA, Inc
- Biocon
- Pfizer Inc.
- Apotex Inc
- Reddy's Laboratories Ltd
- Cadila Pharmaceuticals.
- Accord Healthcare
- Accure Labs Pvt. Ltd
- Shanghai Henlius Biotech, Inc.
- Janssen Global Services, LLC
- Checkpoint Therapeutics, Inc.

Product Code: CMI2458

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
Market Definition and Scope
Executive Summary
- Market Snapshot, By Strength
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Novel Product Launch/Approval
Merger-Acquisition Scenario
PEST Analysis
Regulatory Scenario
Reimbursement Scenario
Epidemiology

4. Global Pemetrexed Market, By Strength, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
100mg
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
500mg
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Pemetrexed Market, By Distribution Channel, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Pemetrexed Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profiles
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Stada Arzneimittel AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eagle Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Fresenius Kabi USA
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Teva Pharmaceuticals USA, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Biocon
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Apotex Inc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Reddy's Laboratories Ltd
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cadila Pharmaceuticals.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Accord Healthcare
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Accure Labs Pvt. Ltd
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Shanghai Henlius Biotech, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Janssen Global Services, LLC,
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Checkpoint Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
  - Analyst Views